SCHEMBL4748923

SCHEMBL4748923

CCCCOC(=O)N1CCC1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.48
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 1/20 0.46
GBA2 Q9HCG7 1/20 0.43
ACE P12821 2/20 0.40
ACE2 Q9BYF1 2/20 0.40
ALDH1A1 P00352 3/20 0.40
ATM Q13315 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
S1PR5 Q9H228 1/20 0.36
BCHE P06276 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5491802 1.00 RAB9A (0.50) RAB9AL3MBTL1LMNASMN1; SMN2POLB
SCHEMBL7672219 1.00 RAB9A (0.50) RAB9AL3MBTL1LMNASMN1; SMN2POLB
SCHEMBL5493674 0.91 RAB9A (0.62) RAB9AL3MBTL1LMNASMN1; SMN2ACE
SCHEMBL2634067 0.91 RAB9A (0.62) RAB9AL3MBTL1LMNASMN1; SMN2ACE
SCHEMBL695608 0.91 RAB9A (0.62) RAB9AL3MBTL1LMNASMN1; SMN2ACE
SCHEMBL7815566 0.89 RAB9A (0.57) RAB9AL3MBTL1LMNASMN1; SMN2POLB
SCHEMBL3710312 0.89 RAB9A (0.57) RAB9AL3MBTL1LMNASMN1; SMN2POLB
SCHEMBL9464451 0.89 RAB9A (0.61) RAB9AL3MBTL1LMNASMN1; SMN2ACE
SCHEMBL7811720 0.89 RAB9A (0.57) RAB9AL3MBTL1LMNASMN1; SMN2POLB
SCHEMBL29543336 0.87 LMNA (0.46) RAB9AL3MBTL1LMNASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 WO disclosed
WO-2023250157-A9 INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE CORNELL UNIVERSITY (US) 2024-01-25 WO disclosed
WO-2023250157-A1 INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE CORNELL UNIVERSITY (US) 2023-12-28 WO disclosed
EP-3759091-A1 SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY Thomas Helledays stiftelse för medicinsk forskning (SE) 2021-01-06 EP disclosed
EP-3386992-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE Janssen Pharmaceutica, N.V. (BE) 2018-10-17 EP disclosed
WO-2017100668-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2017-06-15 WO disclosed
WO-2008135525-A2 SUBSTITUTED AZETIDINES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-11-13 WO disclosed
EP-1863797-A1 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY AstraZeneca AB (SE) 2007-12-12 EP disclosed
EP-1490043-A4 SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS MERCK & CO INC (US) 2007-05-30 EP disclosed
WO-2006100461-A1 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2006-09-28 WO disclosed
EP-1490043-A2 SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS Merck & Co., Inc. (US) 2004-12-29 EP disclosed
WO-2003082190-A2 SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS MERCK & CO., INC. (US) 2003-10-09 WO disclosed